2026-04-13T01:12:06Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/75712025-10-24T10:31:49Zcom_2072_378070com_2072_378040col_2072_378092

Overnight switch from levetiracetam to brivaracetam: safety and tolerability Salas Puig, Xavier Quintana Luque, Manuel Seijo Raposo, Ivan Manuel Santamarina Pérez, Estevo Fonseca Hernandez, Elena Toledo Argany, Manuel Abraira del Fresno, Laura Institut Català de la Salut Unitat d’Epilèpsia, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Anticonvulsius - Ús terapèutic Epilèpsia - Tractament Avaluació de resultats (Assistència sanitària) CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Central Nervous System Agents::Anticonvulsants Other subheadings::Other subheadings::Other subheadings::/administration & dosage ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Epilepsy COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos del sistema nervioso central::anticonvulsivantes Otros calificadores::Otros calificadores::Otros calificadores::/administración & dosificación TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::epilepsia Brivaracetam; Epilepsy; Tolerability Brivaracetam; Epilepsia; Tolerabilidad Brivaracetam; Epilèpsia; Tolerabilitat Brivaracetam is a newer antiseizure medication than levetiracetam. It has a more selective action on the synaptic vesicle glycoprotein 2A binding site, and it seems to provide a more favorable neuropsychiatric profile. The aim of this study was to assess the safety and tolerability of an overnight switch from levetiracetam to brivaracetam. This was a retrospective descriptive study including patients with epilepsy treated with levetiracetam, who switched due to inefficacy or previous adverse events (AEs). In total, forty-one patients were included (mean age 40.9 ± 17.8 years, women 48.8%). Focal epilepsy represented 75.6% (n = 31) of patients (structural cause [n = 25], unknown cause [n = 6]). Four patients had idiopathic generalized epilepsy, two had developmental and epileptic encephalopathy and four patients were unclassified. The reason to start brivaracetam was inefficacy in 53.7% (n = 22), AEs in 65.9% (25/27 neuropsychiatric) and both in 19.5% (n = 8). Brivaracetam-related AEs were reported in 24.4%. Neuropsychological AEs associated with the previous use of levetiracetam improved in 76% of patients. Treatment was discontinued in 19.5% patients. Patients’ reported seizure frequency improved, worsened and remained stable in 26.8%, 12.2%, and 61.0% of the cases, respectively. An overnight switching to brivaracetam is safe and well tolerated. This treatment can improve levetiracetam-related neuropsychiatric AEs. 2022-05-24T06:57:29Z 2022-05-24T06:57:29Z 2021 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Abraira L, Salas-Puig J, Quintana M, Seijo-Raposo IM, Santamarina E, Fonseca E, et al. Overnight switch from levetiracetam to brivaracetam: safety and tolerability. Epilepsy Behav Reports. 2021;16:100504. 2589-9864 https://hdl.handle.net/11351/7571 10.1016/j.ebr.2021.100504 34901817 000730415800003 http://hdl.handle.net/11351/7571 eng Epilepsy & Behavior Reports;16 https://doi.org/10.1016/j.ebr.2021.100504 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Elsevier Scientia